Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease - WAGM
Submitted by Anonymous (not verified) on Fri, 10/22/2021 - 04:59
